You have 9 free searches left this month | for more free features.

Trastuzumab

Showing 1 - 25 of 1,505

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Malignant Solid Tumor Trial in Philadelphia (Biopsy, Biospecimen Collection, Echocardiography)

Active, not recruiting
  • Malignant Solid Neoplasm
  • Biopsy
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Nov 15, 2023

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic Trial in Boston (Sacituzumab Govitecan,

Not yet recruiting
  • Her 2 Positive Breast Cancer
  • +2 more
  • Sacituzumab Govitecan
  • +2 more
  • Boston, Massachusetts
  • +1 more
Oct 25, 2023

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

GastroEsophageal Cancer, Gastric Cancer Trial in Tampa (Neratinib, Trastuzumab, Oxaliplatin)

Recruiting
  • GastroEsophageal Cancer
  • Gastric Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Oct 25, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Tumor in the Brain Trial in Duarte

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Copper Cu 64-DOTA-Trastuzumab
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

Not yet recruiting
  • Stomach Neoplasm
  • (no location specified)
Oct 16, 2023

Breast Cancer Female Trial (Pyrotinib and Trastuzumab)

Not yet recruiting
  • Breast Cancer Female
  • Pyrotinib and Trastuzumab
  • (no location specified)
Sep 11, 2023

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma Trial in Scottsdale,

Not yet recruiting
  • Metastatic Colon Adenocarcinoma
  • +5 more
  • Trastuzumab
  • +2 more
  • Scottsdale, Arizona
  • +2 more
Jan 31, 2023

Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)

Completed
  • Advanced Gastric Carcinoma
  • Trastuzumab
  • +2 more
  • Dhaka, Bangladesh
    Bangabandhu Sheikh Mujib Medical University
Aug 15, 2023

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Active, not recruiting
  • Breast Cancer
  • Pyrotinib Plus Trastuzumab
  • Pertuzumab Plus Trastuzumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 5, 2022

Breast Cancer Trial (Pyrotinib, Trastuzumab, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Apr 22, 2023

HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

Not yet recruiting
  • HER2-positive Breast Cancer
  • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
  • (no location specified)
Jul 20, 2023

Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

Recruiting
  • Early-stage Breast Cancer
  • +4 more
  • Trastuzumab and nelatinib
  • Trastuzumab and Parstuzumab
  • Guangzhou, China
    Sun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Brain Cancer, Glioblastoma, Metastatic Cancer Trial in New York (Trastuzumab deruxtecan)

Recruiting
  • Brain Cancer
  • +4 more
  • Trastuzumab deruxtecan
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Sep 22, 2023

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

Recruiting
  • Advanced Breast Cancer
  • +2 more
  • Trastuzumab Emtansine (T-DM1)
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023

t Pathologic Complete Response Observed in HER2 Positive Breast

Completed
  • HER2+ Breast Cancer
  • Trastuzumab
  • Rawalpindi, Punjab, Pakistan
    Rawalpindi Medical University
Jun 26, 2023

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

Safety and Efficacy of Trastuzumab BS

Not yet recruiting
  • Gastric Cancer
  • TRASTUZUMAB BS
  • (no location specified)
Dec 19, 2022

Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Recruiting
  • Breast Cancer
  • pyrotinib combined with trastuzumab, dalpiciclib and letrozole
  • Yantai, Shandong, China
    Yantai Yuhuangding Hospital
Mar 23, 2023

Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)

Recruiting
  • Breast Cancer
  • Neoadjuvant
  • pyrotinib,Trastuzumab´╝îcarboplatin´╝îAlbumin paclitaxel
  • Wuhan, Hubei, China
  • +1 more
Aug 18, 2023

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

Not yet recruiting
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • (no location specified)
Nov 7, 2023